medigraphic.com
Medicina Universitaria

2008, Number 38

<< Back Next >>

Med Univer 2008; 10 (38)

Autologous hematopoietic cell transplantation from bone marrow for the treatment of chronic ischemia in peripheral arterial diseases in the diabetic patient. Preliminary report

Muñoz MGE, Salinas DR, Gómez AD, Guzmán LS, Villarreal PJZ, Campos CMA, Cuéllar BAB, Treviño GM, Ruiz DG, Tarin ALC, Vázquez GE

Language: Spanish
References: 25
Page: 29-35
PDF size: 240.32 Kb.


ABSTRACT

Background: Peripheral Arterial Disease is a frequent public health problem and a main complication of diabetes. Multiple reports show that endothelial progenitor cells can differentiate into endothelial cells and produce neoangiogenesis. Patients with diabetes are known to have impaired endothelial progenitor cell function. It has also been suggested that neoangiogenesis might be induced by inflammation only.
Objective: To compare the autologous endothelial progenitor cell transplantation obtained from the bone marrow to treat advanced peripheral vascular disease in patients with diabetes mellitus, and in another control group, stimulating the bone marrow and infiltrating only the substrate in the lower limbs
Methods: This study compared autologous endothelial progenitor cell transplant with inflammation, both prior G-CSF stimulation. Group I (n=5) was induced with G-CSF and injected with endothelial progenitor cell substrate (albumin 5%). Group II (n=8) was induced with GCSF and injected with autologous endothelial progenitor cells.
Results: In comparison, group I showed clinical and transcutaneous oximetry improvement in 50% of the patients, which was statistically significant, in group II improvement was observed in all the parameters, being statistically significant.
Conclusions: This study shows a significant advance in treatment with hematopoietic stem cells in patients who have no other alternative for improving their quality of life.


REFERENCES

  1. Bauer E. Foot ulcers. N Engl J Med 2000;343:787-93.

  2. Zimmy S. Early detection of microcirculatory impairment in diabetic patients with foot at risk. Diabetes Care 2001;24:1810-4.

  3. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002;106:2781-6.

  4. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-9.

  5. Asahara T, Murohara T, Sullivan A, Silver M, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.

  6. Hill JM, Zalos G, Halcox JP, Schenke W, Waclawiw M, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.

  7. Curti A, Fogli M, Ratta M, Biasco G, Tura S, Lemoli R. Dendritic cell differentiation from hematopoietic CD34+ progenitor cells. J Biol Regul Homeost Agents 2001;15:49-52.

  8. World Health Organization. The cost of diabetes. WHO Fact Sheet No. 236. 2002, Jun 1 2006.

  9. Escobedo J. Incidencia y letalidad de las complicaciones agudas y crónicas de la diabetes mellitus en México. Salud Publica Mex 1996;38:236-42.

  10. Lenhard MJ, Maser RE. Sharing the pain. Diabetes Care 2003;26:1606-7.

  11. Boyko J, Ahroni J, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information. The Seattle diabetic foot study. Diabetes Care 2006;29:1202-7.

  12. Kalani M. Transcutaneous oxigen pressure and toe and toe blood pressure as predictors for outcome of diabetic ulcers. Diabetes Care 1999;22:127-31.

  13. Sheffield PJ. Clinical applications of TcpO2 in hyperbaric oxygen threatment. Blood Gas News 1998;72:10-13.

  14. Elio M. Gas transcutaneous determination in diabetic critical limb ischemia. Diabetes Care 2005;28:2081-4.

  15. Guilmot JL, Diot E. The role of drug therapy in the treatment of critical ischemia of the lower limbs. Presse Med 1999;28:647-50.

  16. Faries PL, Arora S, Pomposelli FB Jr, Pulling MC, Smakowski P, et al. The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years. J Vasc Surg 2000;31:50-59.

  17. Levy BI. Diabetes and ischemia of lower extremities: potential strategies of therapeutic angiogenesis. Journ Annu Diabetol Hotel Dieu 2005;27-32.

  18. Silvestre JS. Diabetes and peripheral arterial occlusive disease: therapeutic potential and pro-angiogenic strategies. Ann Cardiol Angeiol 2006;55:100-3.

  19. Rice TW. Optimal medical management of peripheral arterial disease. Vasc Endovasc Surg 2006;40:312-27.

  20. Zachary T. American Diabetes Association 60th scientific sessions, 2000. Diabetes Care 2001;24:946-51.

  21. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cells improves critical limb ischemia. Diabetes Care 2005;28:2155-60.

  22. Edward A. Hematopoietic stem cell transplantation. N Engl J Med 2006;354:1813-26.

  23. Zentilin L. Bone marrow mononuclear cells are recruited to the sites of VEGF- induced neovascularization but are not incorporated into the newly formed vessels. Blood 2006;107:3546-54.

  24. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, et al. In vitro differentiation of endothelial cells from AC133- positive progenitor cells. Blood 2000;95:3106-12.

  25. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 2004;95:343-53.




2020     |     www.medigraphic.com